I understood what you meant so no problem. This endpoint suggests this trial IS being used as an initial test for benefit found in rGBM as the second most important endpoint. You have seen flipper44’s posts about the ongoing trial in rGBM and the apparent involvement of or contact with Merck employees or a former Merck employee (Mr Roger Perlmutter). The news is going to be “Bigger” than almost anyone realizes yet. Biosectinvestor’s comments about RMAT not long ago also tie in. We are going to have fun and this message board is going to blow up with comments from those who have been watching mostly on the sidelines and I am already very happy for them as they were the ones targeted with FUD to get them to sell. Looking back I remember how concerned I was about investor sentiment at the time of the 2017 annual shareholders meeting and how important it was that each of the leadership team be there to reassure investors. That was a very critical time for retail investor support. Best wishes.
Market Data 
Markets 
AI
